Loading clinical trials...
Loading clinical trials...
An Exploratory Clinical Study of the Safety and Efficacy of Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Subjects with Relapsed/Refractory Hematologic Malignancy
Conditions
Interventions
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
Fludarabine
+1 more
Locations
1
China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Start Date
September 18, 2023
Primary Completion Date
March 18, 2025
Completion Date
March 18, 2026
Last Updated
January 3, 2025
NCT06532643
NCT05713110
NCT01239108
NCT05400876
NCT05271279
NCT02259010
Lead Sponsor
Affiliated Hospital of Nantong University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions